apollo
logo
0Login
Introducing Our Latest Arrival!
Paclibenz-260 mg Injection 43.4 ml

Paclibenz-260 mg Injection 43.4 ml

Prescription drug
 Trailing icon
Consult Doctor

Composition

PACLITAXEL-260MG

Manufacturer/Marketer

Admac Pharma Ltd

Consume Type

PARENTERAL

Return Policy

Not Returnable

Expires on or after

Apr-26

for this medicine

About Paclibenz-260 mg Injection 43.4 ml

Paclibenz-260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer.

Paclibenz-260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by stopping cell division and preventing the growth of certain cancer cells.

In some cases, Paclibenz-260 mg Injection 43.4 ml may cause common side effects, such as nausea, vomiting, mild diarrhoea, and joint or muscle pain. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.

Consult your doctor if you are pregnant, breastfeeding, think you may be pregnant or are planning pregnancy. Paclibenz-260 mg Injection 43.4 ml is not recommended for children below 18 years. Inform your doctor about your health condition and medications to rule out any side effects.

Uses of Paclibenz-260 mg Injection 43.4 ml

Treatment of Ovarian cancer, breast cancer, non-small cell lung cancer

Medicinal Benefits

Paclibenz-260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. It may also be used when other treatments have failed or in combination with other treatments. Paclibenz-260 mg Injection 43.4 ml may also be indicated in patients with Kaposi’s sarcoma (cancer that develops from the cells that line lymph or blood vessels) associated with AIDS (Acquired Immuno-Deficiency Syndrome), where other treatments have not been effective. Paclibenz-260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by preventing the growth of certain cancer cells. 

Directions for Use

Paclibenz-260 mg Injection 43.4 ml will be administered by a healthcare professional; do not self-administer.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Paclibenz-260 mg Injection 43.4 ml

  • Nausea
  • Vomiting
  • Diarrhoea
  • Hair loss
  • Joint or muscle pain
  • Decreased blood cell count

Drug Warnings

Do not take Paclibenz-260 mg Injection 43.4 ml if you are allergic to any of its components, if your white blood cell or platelet count is very low, if you have a serious uncontrolled infection, and Paclibenz-260 mg Injection 43.4 ml has to be given for the treatment of Kaposi’s sarcoma (cancer that causes lesions in soft tissues), or if you have severe liver problems. Inform your doctor if you have heart disease, abnormal blood cell counts, irregular heartbeat, tingling, numbness, or burning sensation in fingers or toes, visual problems, if you are on radiation therapy, or if you have Kaposi’s sarcoma and have a sore or inflamed mouth. Also, inform your doctor if you are pregnant, breastfeeding, think you are pregnant or planning pregnancy.

Drug Interactions

Drug-Drug Interactions: Inform your doctor if you are taking antibiotics (rifampicin, erythromycin), anti-fungal (ketoconazole), anti-depressant (fluoxetine), anti-epileptic (carbamazepine, phenytoin), lipid regulating agent (gemfibrozil), antacid (cimetidine), medicines used to treat HIV/AIDS (ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine), anti-platelet (clopidogrel).

Drug-Food Interactions: No interactions found.

Drug-Disease Interactions: Inform your doctor if you have a very low white blood cell or platelet count, a serious uncontrolled infection, or severe liver problems.

Drug-Drug Interactions Checker List

  • RIFAMPICIN
  • ERYTHROMYCIN
  • KETOCONAZOLE
  • FLUOXETINE
  • CARBAMAZEPINE
  • PHENYTOIN
  • GEMFIBROZIL
  • CIMETIDINE
  • RITONAVIR
  • SAQUINAVIR
  • INDINAVIR
  • NELFINAVIR
  • EFAVIRENZ
  • NEVIRAPINE
  • CLOPIDOGREL

Habit Forming

No

Diet & Lifestyle Advise

  • Eat a healthy diet and exercise regularly to maintain proper weight.
  • Avoid smoking and alcohol consumption.
  • Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, herbs and spices in your diet.
  • Avoid fast food, fried food, processed meats, refined carbs and added sugar.
  • Get optimal sleep; rest well.

Special Advise

  • Your doctor may advise regular blood tests to check for liver activity, kidney function and blood cell count.
  • You and/or your partner should use reliable contraception during treatment with Paclibenz-260 mg Injection 43.4 ml and for at least six months after the treatment.

Disease/Condition Glossary

Breast cancer: It is a type of cancer that develops in the breast when the breast cells begin to grow abnormally. Symptoms of breast cancer include a lump in the breast or tissue thickening which feels different than the normal surrounding tissues, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin, and a lump or swelling under the arm.

Ovarian Cancer: Ovarian cancer occurs when abnormal cells grow and multiply in the ovaries and fallopian tubes. Signs and symptoms include pain, swelling, or a feeling of pressure in the pelvis or abdomen, frequent or sudden urge to urinate, feeling full or trouble eating, a lump in the pelvic area, gas, bloating, or constipation.

Non-small cell lung cancer: It is a disease in which cancer cells form in the tissues of the lungs. Smoking is the major risk factor for non-small cell lung cancer. Symptoms include a cough that does not go away and shortness of breath.

bannner image

Alcohol

Consult your doctor

It is not known if alcohol interacts with this medicine. Please consult your doctor.

bannner image

Pregnancy

Unsafe

Paclibenz-260 mg Injection 43.4 ml must not be given during pregnancy unless clearly necessary, as it may cause birth defects. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Paclibenz-260 mg Injection 43.4 ml.

bannner image

Breast Feeding

Unsafe

Avoid breastfeeding whilst on treatment with Paclibenz-260 mg Injection 43.4 ml. Do not restart breastfeeding until your doctor tells you it is safe to do so.

bannner image

Driving

Caution

Paclibenz-260 mg Injection 43.4 ml may cause dizziness, tiredness, or nausea. Drive or operate heavy machinery only if you are alert.

bannner image

Liver

Caution

Do not use Paclibenz-260 mg Injection 43.4 ml if you have severe liver problems. If you have a history of liver disease, inform your doctor before receiving Paclibenz-260 mg Injection 43.4 ml.

bannner image

Kidney

Consult your doctor

If you have a history of kidney diseases, inform your doctor before receiving Paclibenz-260 mg Injection 43.4 ml. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.

bannner image

Children

Unsafe

Paclibenz-260 mg Injection 43.4 ml is not recommended for children below 18 years due to a lack of data on the safety and effectiveness.

Country of origin

India

Manufacturer/Marketer address

14, Sarvoday Estate, Narol Isanpur Highway, Isanpur, Near Anand Hotel - 382443, Gujrat.
Other Info - PAC0171

Author Details

Doctor imageWe provide you with authentic, trustworthy and relevant information

FAQs

Paclibenz-260 mg Injection 43.4 ml is used to treat Ovarian cancer, breast cancer, non-small cell lung cancer.
Paclibenz-260 mg Injection 43.4 ml works by stopping cell division and preventing the growth of certain cancer cells.
Paclibenz-260 mg Injection 43.4 ml might cause sterility which could be permanent. Please talk to your doctor if you have any concerns.
The most common side effect of Paclibenz-260 mg Injection 43.4 ml is hair loss. The hair may grow back after the treatment with Paclibenz-260 mg Injection 43.4 ml is finished. However, consult your doctor if you have any concerns.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.